News

Filter

Current filters:

ZonegranRegulation

FDA clears Eisai Zonegran facility in UK for US exports

FDA clears Eisai Zonegran facility in UK for US exports

15-10-2013

Eisai says the US Food and Drug Administration has approved the US supply of the epilepsy drug Zonegran…

EisaiEuropeNeurologicalNorth AmericaPharmaceuticalProductionRegulationZonegran

Eisai gains Swiss approval for Zonegran and Canadian OK for Fycompa

11-07-2013

Japanese drug major Eisai (TYO: 4205) says that Zonegran (zonisamide) has been approved by Switzerland's…

EisaiEuropeFycompaNeurologicalNorth AmericaPharmaceuticalRegulationZonegran

News briefs: Priority review for ocriplasmin; Zonegran monotherapy in EU

03-07-2012

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR) says that the US Food and Drug Administration…

EisaiEuropeNeurologicalNorth AmericaocriplasminOphthalmicsPharmaceuticalRegulationThromboGenicsZonegran

Zonegran Russian approval prompts Eisai's expansion in that market

28-06-2012

Eisai (TYO: 4523), a leading Japanese drugmaker, says it plans to expand its operations into Russia,…

EisaiEuropeFycompaHalavenMarkets & MarketingNeurologicalPharmaceuticalRegulationZonegran

Eisai epilepsy drug delayed by US FDA, but Zonegran use extension filing accepted in EU

01-08-2011

There was disappointment for Japanese drug major Eisai (TYO: 4523) last week when the US Food and Drug…

EisaiEuropeNeurologicalNorth AmericaperampanelPharmaceuticalRegulationZonegran

Eisai to file Zonegran as first-line epilepsy therapy in Europe on good trial results

13-07-2011

Based on the positive results of a late-stage clinical trial, Japanese drug major Eisai’s (TYO:…

EisaiEuropeNeurologicalPharmaceuticalRegulationResearchZonegran

Back to top